ShanghaiJune 12, 2026 /PRNewswire/ — Recently, Revvity’s new single- and dual-test blood nucleic acid screening kit—the Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus (Types 1+2) Nucleic Acid Detection Kit (PCR-Fluorescence Method)—was officially approved for market launch. This product, with its three core advantages of “high sensitivity, high efficiency, and low loss,” is specifically designed to meet the increasingly stringent testing demands of China’s blood collection and supply institutions and clinical laboratories, offering a more tailored integrated solution for local blood nucleic acid screening scenarios.
As blood collection and supply institutions continue to raise requirements for the accuracy, reporting timeliness, and sample splitting loss management of blood nucleic acid screening tests, miniaturized and集约化 detection has become a mainstream trend in the industry. The newly launched kit not only features a single-test mode but also an innovative dual-sample pooled testing mode, which effectively balances testing throughput and operational efficiency while considering detection sensitivity, throughput, and sample loss.
This new product employs single-tube multiplex PCR technology, detecting three pathogens in a single reaction and directly identifying the reactive pathogen type; the detection of Hepatitis B Virus DNA, Hepatitis C Virus RNA, and Human Immunodeficiency Virus Type 1 RNA uses dual-fragment combined detection. The product utilizes automated magnetic bead-based nucleic acid extraction, with M-PVA-coated magnetic particles effectively adsorbing viral nucleic acids. It incorporates an internal standard system to control the validity of the sample testing process and results, preventing false-negative outcomes, and uses a UNG-dUTP contamination prevention system to avoid PCR amplification product contamination.
The new product covers HBV DNA, HCV RNA, and HIV-RNA analysis items across genotypes A-H, subtypes 1-6, and HIV-1 groups M, O, N, and Type 2, with no cross-reactivity with related pathogens.
Minimum detection limits:
|
Note: The data listed in the table are derived from test results of three batches of reagents. A 95% Probit statistical analysis was performed on the detection results of each analysis item under the two testing modes for the three batches of reagents, with the average value taken as the minimum detection limit for each analysis item under the corresponding testing mode. |
Leveraging global technological advantages and accumulated local expertise, this newly launched product is compatible with automated screening platforms such as the Lean series and Pre-NAT II, and also injects new momentum into the ACES automated integration system, forming a comprehensive “reagent + instrument + system” blood safety screening solution. This achieves a fully unattended “sample in, result out” process, delivering higher integration, intelligence, and stability to safeguard transfusion safety and public health defenses.
Rooted in China, Driving Transfusion Safety Through Localized Innovation
Revvity’s subsidiary, Haoyuan Bio, has nearly 30 years of technical expertise in nucleic acid blood screening and has been a witness and driver of the development of China’s blood screening industry. Deeply rooted in the blood screening field, we provide products and services to over 40% of China’s blood stations, pioneering the “triple-combo” multiplex nucleic acid blood screening and leading the iteration of blood screening technology. In the future, Revvity will continue to rely on global resource advantages and local manufacturing capabilities, focusing on precision, efficiency, and low consumption, to offer blood safety screening solutions that better meet China’s needs for blood collection and supply institutions and clinical laboratories. We aim to protect the source of life with technology, build a safety barrier with expertise, and contribute innovative professional strength to the “Healthy China” strategy.
*Parameters mentioned in the text are sourced from the product manual.